title: [A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20mgSbV/day for 20 days to treat cutaneous leishmaniasis].
abstract: Seventy-nine patients with cutaneous leishmaniasis were included in this study. The experimental group (n = 38) was treated with pentamidine isothionate in a dose of 4mg/kg/day on alternate days, for one week. The control group (n = 41) was treated with N-methylglucamine in a dose of 20mgSbV/kg/day for 20 days. Twenty-one isolates were identified using monoclonal antibody technique. We characterized Leishmania (Viannia) braziliensis, most frequently. There was a cure rate of 71.05% of the patients in the experimental group and 73.17% in the control group (p = 0.47). We found a statistical significance regarding frequency of ECG alterations between the experimental and control group (p<0.05). In our study pentamidine was as effective as antimonial for the treatment of american cutaneous leishmaniasis. It proved to be a safer drug considering heart toxicity. Moreover, it requires less time to complete the treatment.
authors.affiliation: Serviço de Dermatologia, Hospital Universitário de Brasília, Brasília, DF, Brasil. rnrsampaio@hotmail.com
authors.forename: Carmen Déa Ribeiro
authors.initials: CD
authors.lastname: de Paula
authors.forename: João Herman Duarte
authors.initials: JH
authors.lastname: Sampaio
authors.forename: Danielle Rizzo
authors.initials: DR
authors.lastname: Cardoso
authors.forename: Raimunda Nonata Ribeiro
authors.initials: RN
authors.lastname: Sampaio
mesh_terms: D000328:Adult; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D004562:Electrocardiography; D005500:Follow-Up Studies; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008536:Meglumine / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D010419:Pentamidine / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D011446:Prospective Studies
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D010419:Pentamidine; D008536:Meglumine; D000077485:Meglumine Antimoniate